Ironwood's IW-3718 meets primary in Phase IIb to treat GERD

Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) said top-line data from a double-blind, U.S. Phase IIb trial in 282 patients with uncontrolled gastroesophageal reflux disease (GERD) showed that twice-daily 1,500 mg oral IW-3718 plus a proton

Read the full 333 word article

User Sign In